Source comparison
Head-to-Head Comparison: Full-Thickness Excisional Wound Research
In matched experimental groups (C57BL/6, 6mm full-thickness excisional dorsal wound): TB-500 6mg/kg s.c. days 0/3/7 vs GHK-Cu 2mg/kg s.c. daily days 0-14 vs combination vs vehicle: Day 7 outcomes: wound closure — TB-500 72±4% vs GHK-Cu 58±5% vs combination 78±
This comparison does not assign a generated winner or score.
- In matched experimental groups (C57BL/6, 6mm full-thickness excisional dorsal wound): TB-500 6mg/kg s.c. days 0/3/7 vs GHK-Cu 2mg/kg s.c. daily days 0-14 vs combination vs vehicle:
- Day 7 outcomes: wound closure — TB-500 72±4% vs GHK-Cu 58±5% vs combination 78±4% vs vehicle 48±5% (TB-500 superior at day 7, combination best); re-epithelialisation — TB-500 keratinocyte tongue 3.8±0.3mm vs GHK-Cu 2.8±0.3mm vs combination 4.2±0.3mm; microvessel density CD31+ — TB-500 9.4/HPF vs GHK-Cu 7.8/HPF vs combination 10.2/HPF vs vehicle 6.4/HPF.
- Day 14 outcomes: Sircol collagen content — GHK-Cu 2.8±0.2mg/wound vs TB-500 1.8±0.2mg/wound vs combination 3.2±0.2mg/wound vs vehicle 1.4±0.2mg/wound (GHK-Cu superior by day 14, combination best); tensile strength (uniaxial testing: peak failure load) — GHK-Cu 1.8±0.2N vs TB-500 1.4±0.2N vs combination 2.2±0.2N vs vehicle 1.0±0.2N; sirius red type I collagen proportion — GHK-Cu 74±4% vs TB-500 62±4% vs combination 78±4% vs vehicle 52±4%.
- This temporal reversal — TB-500 superior at day 7, GHK-Cu superior at day 14 — mechanistically validates the phase-specific activity model and demonstrates additive combination benefit across all wound healing endpoints.